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A B S T R A C T
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common
karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormali-
ties (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic
cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients,
of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical
siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse
incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year sur-
vival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate
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analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44
to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41
to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q)
abnormality.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Myelodysplastic syndromes (MDS) are heterogeneous
clonal hematopoietic stem cell malignancies characterized by
ineffective hematopoiesis with peripheral blood cytopenia and
a propensity to transform to acute leukemia [1]. However, the
course of the disease is highly variable [2]. The World Health
Organization proposed a cytologic classification [3] and revised
it in 2008 [4]. The deletion (5q) karyotype (del [5q]) is the
most common karyotypic abnormality in de novo MDS, oc-
curring in approximately 10% to 20% of patients with MDS.
An increased number of blasts and additional karyo-
typic abnormalities (del [5q]+) are associated with a poorer
prognosis [5]. Indeed, the outcome of patients with MDS is
markedly affected by clonal chromosomal abnormalities [6,7].
These are taken into account in the International Prognos-
tic Scoring System (IPSS), which in addition to the marrow
blast count and peripheral blood cytopenia, considers 3 cy-
togenetic categories: patients with a normal karyotype, del
(5q), del (20q), or -Y are classed as having a good risk, whereas
patients with a complex karyotype (ie, >3 anomalies) or chro-
mosome 7 abnormalities are considered to have a poor risk.
All other chromosomal abnormalities are considered to carry
an intermediate risk [8]. A revised version of the IPSS (R-
IPSS) has been established that incorporates the blood
transfusion requirements [9]. In the classic IPSS, del (5q), if
associated with at least 2 other cytogenetic abnormalities,
is classed as having a poor risk, whereas in the R-IPSS it is
considered to carry a good risk in the absence of other cy-
togenetic abnormalities.
The 5q syndrome was first described in 1974 [10]. Ac-
cording to the World Health Organization classification it is
a specific MDS subgroup [4]. This distinct syndrome occurs
predominantly (>60%) in women and is associated with an
isolated 5q deletion, erythroid hypoplasia, abnormal plate-
lets, a relatively benign clinical course, and a probability of
leukemic transformation of 10% to 20% [5].
The karyotype is a prognostic factor for survival in MDS
and acute myeloid leukemia. In patients with (de novo) acute
myeloid leukemia the loss of 5q often occurs in combina-
tion with additional chromosomal abnormalities and is
generally considered to be a marker of high-risk disease [7].
Conversely, in MDS patients the 5q deletion is favorable.
However, it is not known how the combination of del (5q)
plus additional cytogenetic abnormalities and/or a blast excess
affects the outcome of patients undergoing allogeneic stem
cell transplantation. In this work we examined the impact,
in MDS patients, of del (5q) as the only cytogenetic abnor-
mality as compared with del (5q) in combination with other
clonal anomalies ([5q]+), with regard to the prognosis after
allogeneic hematopoietic cell transplantation (HCT). We in-
vestigated the outcome of this patient subpopulation




In the EBMT database we found 175 allografted MDS patients with a 5q
deletion. Patients with a syngeneic (n = 1), matched other relative (n = 3),
or mismatched relative (n = 9) graft were excluded, leaving a dataset of 162
individuals. Seventy-six patients had del (5q) as a single abnormality with
(n = 37) or without (n = 39) blasts, whereas 86 had del (5q) plus another cy-
togenetic abnormality with (n = 71) or without (n = 15) blasts. The following
variables were collected and analyzed: patient age at transplantation, in-
terval between diagnosis and transplantation, type of donor (identical sibling
or unrelated), source of stem cells (peripheral blood, bone marrow, or cord
blood), cytogenetic data, and type of conditioning (reduced or standard in-
tensity).
Type of Conditioning
Myeloablative conditioning comprised cyclophosphamide plus high-
dose total body irradiation (>8 Gy) or cyclophosphamide plus high-dose
busulfan (16 mg/kg total dose p.o. or the equivalent i.v. dose), with or without
other high-dose cytotoxic agents and/or antithymocyte globulin or
alemtuzumab. A reduced-intensity conditioning regimen comprised
fludarabine plus intermediate doses of 1 or 2 alkylating agents or low-
dose total body irradiation (2 Gy), with or without antithymocyte globulin
or alemtuzumab. Intermediate doses of alkylating agents consisted of bu-
sulfan (8 to 10 mg/kg, p.o.), melphalan (80 to 140 mg/m2, i.v.),
cyclophosphamide (60 to 120 mg/m2, i.v.), or thiotepa (5 to 10 mg/kg, i.v.).
Statistical Analyses
The primary endpoints were overall survival (OS), relapse-free surviv-
al (RFS), relapse incidence (RI), and nonrelapse mortality (NRM). OS was
defined as the probability of survival after transplantation; death from any
cause was considered an event. Patients alive at the time of the last follow-
up were censored at this date. RFS was calculated as the time to death or
relapse, whichever occurred first, patients surviving relapse-free being cen-
sored at the moment of the last follow-up. The probabilities of OS and RFS
were estimated using the Kaplan-Meier product limit method, and differ-
ences between subgroups were assessed with the log-rank test.
RI was defined as the probability of relapse. NRM was defined as the
probability of any death in the absence of relapse since HCT. For NRM and
RI patients were censored if they were relapse-free and alive at the time of
the last follow-up. The estimates of NRM and RI were calculated using cu-
mulative incidence curves to accommodate competing risks (relapse was
considered to be a competing risk for NRM and vice versa), whereas com-
parisons among subgroups were assessed using Gray’s test. All follow-up
times were censored at 4 years to allow valid comparisons between variables.
A Cox proportional hazards regression was used to assess the impact
of potential prognostic factors on the multivariate analyses. The impact of
these factors on OS, RFS, NRM, and RI was modeled by means of cause-
specific hazards.
All P-values are 2-sided, and P < .05 was considered to be significant. All
analyses were performed using software (R version 3.0.3) and the pack-
ages “prodlim” and “cmprsk”.
RESULTS
Patient and Disease Characteristics
The demographic data of the study population are pre-
sented in Table 1. Seventy-six percent of the patients were
aged ≥ 45 years, two-thirds had a bone marrow blast excess
of >5%, and 47% had only del (5q). Among del (5q) patients
with additional cytogenetic abnormalities, 78 (48%) ful-
filled the criteria of complex karyotype. The IPSS score was
low/intermediate-1 in 49% and 46% and intermediate-2/
high in 51% and 54% at diagnosis and transplantation,
respectively. Allogeneic stem cell transplantation was per-
formed with cells from an identical sibling in 54% of patients,
and the stem cell source was peripheral blood in 73%.
Outcome in the Whole Population
The percentage of engraftment was 92%. With a median
follow-up of 68.2 months (95% confidence interval [CI], 59.3
to 85.0), at 4 years the NRM was 29% (95% CI, 22 to 36) and
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the relapse rate 46% (95% CI, 38 to 54), resulting in a 4-year
estimated OS of 30% (95% CI, 23 to 38) and RFS of 25% (95%
CI, 18 to 33) (Figure 1).
The overall survival by excess of blasts is represented in
Figure 2 and the relapse incidence and non relapse mortal-
ity by excess of blasts are represented in Figure 3.
Graft-versus-Host Disease
The incidences of acute (up to day 100) and chronic graft-
versus-host disease (at 4 years starting from day 100) were
24.7% (95% CI, 17.8 to 31.5) and 44% (95% CI, 33 to 55),
respectively. The incidence of grades I to II acute graft-versus-
host disease was 12% and that of grades III to IV 13%. The
incidences of limited and extended chronic graft-versus-
host disease were 33% and 10%, respectively.
Univariate and Multivariate Analyses
Univariate analyses
In terms of OS at 4 years, the results were better for those
without excess of blast, an IPSS at diagnosis low or
intermediate-1, and there was a trend in favor of patients
younger than age 45 years. All other factors had no impact
on survival: presence or not of additional cytogenetic
abnormalities, type of conditioning regimen, donor type, stem
cell source, recipient–donor cytomegalovirus match,
recipient–donor sex match, and the time from diagnosis to
transplantation (< or >12 months) (Table 2).
Multivariate analysis
All factors found to be significant in the univariate anal-
yses were included in the multivariate analysis (Table 2). In
a multivariate Cox regression analysis the recipient–donor
gender match, recipient–donor cytomegalovirus status, and
interval between diagnosis and treatment did not influence
the outcome.
OS was influenced by the presence of an excess of blasts
(hazard ratio [HR], 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas
female recipients had a more favorable outcome as com-
pared with males (HR, .61; 95% CI, .41 to .90; P = .01). A
significant trend was found for the age category ≥ 45 years
(versus <45 years) (HR, 1.57; 95% CI, .94 to 2.63; P = .09). The
presence of additional cytogenetic abnormalities did not sig-
nificantly affect OS (HR, 1.07; 95% CI, .70 to 1.63; P = .76)
(Table 3).
RFS was influenced by an excess of blasts (HR, 2.02; 95%
CI, 1.26 to 3.24; P < .001), whereas the gender of the recipi-
ent displayed a significant trend in favor of women (HR, .69;
95% CI, 1.009 to .056; P = .056). Additional cytogenetic ab-
normalities and age category were not significantly associated
with RFS.
Concerning the incidence of relapse, an excess of blasts
(HR, 2.24; 95% CI, 1.15 to 4.38; P = .02 and additional cyto-
genetic abnormalities (HR, 1.84; 95% CI, 1.03 to 3.29; P = .04)
had significant influence, whereas the type of donor was
almost significant, with a more favorable outcome for unre-
lated donors (versus identical siblings) (HR, .62; 95% CI, .37
to 1.02; P = .06). Finally, for NRM only the type of donor was
a significant factor, with unrelated donors being less favor-
able (versus identical siblings) (HR, 1.80; 95% CI, 1.09 to 3.31;
P = .02).
DISCUSSION
MDS comprises a wide range of different diseases dis-
playing various prognoses. Except for the del (5q) syndrome,
which has a better prognosis, the outcome may be dismal.
The R-IPSS score has greatly improved our capacity to predict
survival, and the chromosomal abnormality del (5q) is con-
sidered to be a good feature. However, the impact of a 5q
deletion plus additional abnormal cytogenetics is not really
known.
Patients with low-risk MDS can benefit from supportive
care for a long time, but eventually they will become trans-
fusion dependent and some will progress to acute leukemia.
The lag time between diagnosis and transformation to acute
leukemia is much shorter for high-risk MDS patients. In our
study the interval between diagnosis and treatment did not
influence the outcome.
Allogeneic stem cell transplantation is an established cu-
rative option for most patients with advanced stages of MDS.
Conversely, only some patients with low-risk MDS are con-
sidered for treatment by allogeneic HCT. The main reason for
this restrictive approach is the high incidence of procedure-
related mortality, which was as high as 50% to 60% in some
studies on patients transplanted before 1996 [11]. Never-
theless, the populations selected for allogeneic HCT usually
include a high proportion of patients with poor-risk charac-
teristics, such as adverse cytogenetic abnormalities,
therapy-related MDS, high transfusion requirements, marrow
Table 1





































Other combinations 130 80
Del (5q) only
Without blasts 37 23
With blasts 39 24
Del (5q) plus additional cytogenetic
abnormalities
Without blasts 15 9
With blasts 71 43
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; CMV,
cytomegalovirus.
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fibrosis, profound cytopenia, or a poor response to treat-
ment [12].
This retrospective, EBMT registry-based study included 162
patients with MDS and del (5q). An excess of blasts, but not
additional cytogenetic abnormalities, had a major impact on
the outcome. With no excess of blasts the OS at 4 years was
53%, as compared with only 21% in the presence of more than
5% blasts. Women had a better prognosis, whereas there was
a trend to an improved outcome in patients younger than age
45 years.
The outcome of allogeneic HCT in patients with MDS and
a del (5q) karyotype was reported in a retrospective British
study [13]. The major prognostic factor was likewise the blast
count, but, unlike in our work, additional cytogenetic abnor-
malities had a negative impact. Cytogenetic abnormalities are
highly predictive of the outcome after allogeneic bone marrow
transplantation in advanced stages of MDS [14-16]. However,
in another study the presence of cytogenetic abnormalities
in patients with early stages of MDS (refractory anemia or
refractory anemia with ring sideroblast) did not influence the
outcome of allogeneic HCT [17].
We found a better OS for female patients and a trend
toward improved OS for younger ones. The influence of age
on the survival of MDS patients has already been described
[18], with a better survival for patients younger than age 50
years. In contrast, the influence of sex remains under




Excess of blasts: yes vs. no 21% vs. 53% (P < .001) 29% vs. 27% (P = .75) 54% vs. 25% (P = .001)
Cytogenetics abnormalities: yes vs. no 26% vs. 36% (P = .24) 26% vs. 33% (P = .44) 59% vs. 29% (P = .001)
Conditioning regimen: reduced vs. standard 29% vs. 32% (P = .59) 29% vs. 28% (P = .82) 44% vs. 47% (P = .76)
Donor type: unrelated vs. identical sibling 30% vs. 30% (P = .81) 37% vs. 22% (P = .05) 35% vs. 54% (P = .03)
Stem cell source: marrow vs. PB vs. CB 29% vs. 31% vs. 22% (P = .31) 30% vs. 27% vs. 44% (P = .43) 42% vs. 48% vs. 33% (P = .72)
IPSS at diagnosis: low/intermediate-1 vs.
intermediate-2/high
42% vs. 14% (P < .001) 24% vs. 43% (P = .09) 38% vs. 49% (P = .30)
Age: >45 yr vs. <45 yr 25% vs. 46% (P = .06) 29% vs. 27% (P = .80) 47% vs. 42% (P = .42)
CMV match: R−/D− vs. R−/D+ vs. R+/D− vs. R+/D+ 31% vs. 27% vs. 24% vs. 37%
(P = .63)
24% vs. 22% vs. 37% vs. 29%
(P = .54)
55% vs. 65% vs. 38% vs. 35%
(P = .21)
Donor/recipient match: female D/male R vs. other 22% vs. 32% (P = .38) 31% vs. 28% (P = .93) 50% vs. 45% (P = .41)
Time diagnosis to transplantation: >12 mo vs. ≤12 mo 38% vs. 25% (P = .11) 28% vs. 29% (P = .84) 48% vs. 43% (P = .41)
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Figure 2. OS survival after allogeneic stem cell transplantation in patients with a del (5q) karyotype, with or without an excess of blasts.
Figure 3. RI and NRM after allogeneic stem cell transplantation in patients with a del (5q) karyotype, with or without an excess of blasts.
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discussion, particularly in low-risk MDS patients [19]. In these
patients we found a significant effect of age and sex on sur-
vival in the univariate models, whereas the multivariate model
confirmed this effect only for age. Another study concluded
that age and sex and their interaction could influence the
prognostication of patients, but only when using the IPSS
rating [20]. A further study demonstrated that this impact
on the prognosis of del (5q) MDS patients was not only due
to age and sex, although more advanced age and male sex
were important risk factors, but the World Health Organi-
zation classification subtypes also played a role [21]. In the
allogeneic setting, age has previously been identified as an
important prognostic factor [22].
Patients with 5q syndrome respond well to lenalidomide.
Thus, a reduced need for transfusion was reported in 76% of
patients with 67% no longer requiring transfusion, regard-
less of the karyotype complexity, whereas 45% displayed a
complete cytogenetic response [23]. However, no cure was
observed, and the median duration of response was approx-
imately 2 years. Acute myeloid leukemia transformation
occurred in 15% to 21% of patients showing a cytogenetic re-
sponse and in 60% to 67% of nonresponding patients [24-26].
Unfortunately, data on lenalidomide treatment before trans-
plantation were not available for our study.
Recently, TP53 mutations were described as a predictor
of progression in low-risk MDS with del (5q) [27,28]. It was
suggested that the mutated subclone might be insensitive to
lenalidomide and gradually progress, despite a strong inhib-
itory effect on the total proportion of cells carrying del (5q),
leading to transient partial cytogenetic remission. The pres-
ence of clinically relevant subclones with mutations such as
TP53 could lead to genetic instability and disease progres-
sion. However, the p53 mutation has also been described as
a poor prognostic factor after allogeneic stem cell transplan-
tation [29]. In these 2 scenarios patients who do not respond
to lenalidomide and those harboring the TP53 mutation need
more aggressive treatment, and allogeneic HCT could be an
option. Indeed, genetic mutations help to predict clinical out-
comes after allogeneic HCT [30].
There are several limitations to our study. First, the number
of patients was relatively small. Second, patients were trans-
planted over a period of several years, and investigators did
not know why particular del (5q) MDS patients were se-
lected for transplantation. Also, the R-IPSS scores were missing.
Nonetheless, the data presented here shed light on the ex-
pected outcome of HCT in patients with this particular subtype
of MDS.
In summary, MDS patients with cytogenetic abnormali-
ties including a 5q deletion but without excess blasts can
achieve a good outcome when treated by allogeneic stem cell
transplantation, reaching in our study 50% OS at 4 years. These
findings suggest that patients with del (5q) should be trans-
planted early in the course of their disease, before a rising
blast count indicates disease evolution. How should alloge-
neic stem cell transplantation be used in patients with MDS
and del (5q)? Lenalidomide has become an approved and rea-
sonable treatment option that enables a remarkable reduction
in the frequency of transfusion. However, elegant laborato-
ry experiments suggest that lenalidomide does not target the
stem cell population in del (5q) MDS patients [31]. Eligible
patients with an increasing number of blasts and del (5q) MDS
should be considered for allogeneic stem cell transplanta-
tion, as likewise patients who do not or no longer respond
to lenalidomide.
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